Lung Adenocarcinoma — Research

Lung Adenocarcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-13	17,778	`("Adenocarcinoma of Lung"[mh] OR "Adenocarcinoma, Lung"[mh] OR "Adenocarcinomas, Lung"[mh])`	2026-09-13	pubmed
Last 5 years	2021-01-01 → 2026-12-31	7,869	`("Adenocarcinoma of Lung"[mh] OR "Adenocarcinoma, Lung"[mh] OR "Adenocarcinomas, Lung"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-13	pubmed
Last 12 months	2025-09-13 → 2026-09-13	1,393	`("Adenocarcinoma of Lung"[mh] OR "Adenocarcinoma, Lung"[mh] OR "Adenocarcinomas, Lung"[mh]) AND (2025/09/13:2026/09/13[dp])`	2026-09-13	pubmed

Data updated 18 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (98)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–50 of 98 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
· Transl Lung Cancer Res · 2023 · PMID 37057124 · validated civic_curation pubmed
High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.
· Oncotarget · 2016 · PMID 26950277 · validated civic_curation pubmed
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
· J Thorac Oncol · 2016 · PMID 26773740 · validated civic_curation pubmed
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).